Oncternal Therapeutics (NASDAQ:ONCT) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock. Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated a neutral rating and issued a $1.30 target price on shares of Oncternal […]
More Stories
Byrna Technologies Inc. (NASDAQ:BYRN) Short Interest Up 10.1% in October
Byrna Technologies Inc. (NASDAQ:BYRN – Get Free Report) was the target of a large increase in short interest during the...
Brixmor Property Group (NYSE:BRX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS
Brixmor Property Group (NYSE:BRX – Get Free Report) issued its quarterly earnings results on Monday. The real estate investment trust...
CBAK Energy Technology, Inc. (NASDAQ:CBAT) Short Interest Update
CBAK Energy Technology, Inc. (NASDAQ:CBAT – Get Free Report) saw a large increase in short interest in October. As of...
Astar (ASTR) Hits Self Reported Market Capitalization of $416.87 Million
Astar (ASTR) traded 2% higher against the U.S. dollar during the 24 hour period ending at 21:00 PM Eastern on...
Boston Properties (NYSE:BXP) Releases FY 2024 Earnings Guidance
Boston Properties (NYSE:BXP – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The...
Ripio Credit Network Price Tops $0.0017 on Major Exchanges (RCN)
Ripio Credit Network (RCN) traded 2.6% higher against the US dollar during the 24-hour period ending at 21:00 PM E.T....